These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26647000)

  • 1. False-Positive 18F-FDG PET/CT Imaging: Dramatic "Flare Response" After Rituximab Administration.
    Skoura E; Ardeshna K; Halsey R; Wan S; Kayani I
    Clin Nucl Med; 2016 Mar; 41(3):e171-2. PubMed ID: 26647000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics.
    Cohen YC; Berger T; Eshel L; Stern D; Bairey O; Raanani P; Shpilberg O
    Isr Med Assoc J; 2017 Jun; 19(6):372-377. PubMed ID: 28647936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results.
    Cortés Romera M; Gámez Cenzano C; Caresia Aróztegui AP; Martín-Comín J; González-Barca E; Ricart Brulles Y; Palacios Abufón A; Robles Barba J; Rodríguez-Bel L; Rossi Seoane S; Fernández de Sevilla A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):135-41. PubMed ID: 21944191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature.
    Hu S; Bansal P; Lynch D; Rojas Hernandez CM; Dayao Z
    J Med Case Rep; 2016 Dec; 10(1):365. PubMed ID: 27998299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.
    Kalkanis D; Stefanovic A; Paes F; Escalon MP; Serafini A; Lossos IS
    Leuk Lymphoma; 2009 Jun; 50(6):904-11. PubMed ID: 19455459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
    Zinzani PL; Gandolfi L; Broccoli A; Argnani L; Fanti S; Pellegrini C; Stefoni V; Derenzini E; Quirini F; Baccarani M
    Cancer; 2011 Mar; 117(5):1010-8. PubMed ID: 20960498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.
    Falchi L; Capello D; Palumbo B; Rauco A; Emili R; Cianciulli M; Pace R; Capparella V; Liberati F; Liberati AM
    Eur J Haematol; 2007 Nov; 79(5):455-61. PubMed ID: 17908180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Follicular lymphoma showing long-term false positive results by FDG-PET after rituximab-containing chemotherapy].
    Miyazaki Y; Nawa Y; Kohashi S; Nakase K; Miyagawa M; Hara M
    Rinsho Ketsueki; 2012 Feb; 53(2):252-4. PubMed ID: 22450588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
    Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
    Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
    Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients.
    Karantanis D; O'eill BP; Subramaniam RM; Witte RJ; Mullan BP; Nathan MA; Lowe VJ; Peller PJ; Wiseman GA
    Nucl Med Commun; 2007 Nov; 28(11):834-41. PubMed ID: 17901765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt's lymphoma.
    Riad R; Omar W; Sidhom I; Zamzam M; Zaky I; Hafez M; Abdel-Dayem HM
    Nucl Med Commun; 2010 Mar; 31(3):232-8. PubMed ID: 20032800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary tracheal and bronchial lymphoma displayed on 18F-FDG PET/CT imaging.
    Jiang L; Chen S; Li Y; Chen G; Shi H
    Clin Nucl Med; 2015 Dec; 40(12):965-6. PubMed ID: 26359558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG-PET/CT in lymphoma: two decades of experience.
    Alvarez Páez AM; Nogueiras Alonso JM; Serena Puig A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):340-9. PubMed ID: 22841459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.